Exchol, capsules 250 mg 50 pcs

Exchol – hepatoprotective agent, has choleretic effect.

Limits the synthesis of cholesterol in the liver, its absorption in the intestine and its concentration in the bile, increases the solubility of cholesterol in the biliary system, stimulates the formation and excretion of bile.

Limits bile lithogenicity, increases the content of bile acids in it; causes intensification of gastric and pancreatic secretion, increases lipase activity, has hypoglycemic effect. Causes partial or complete dissolution of cholesterol stones when administered enterally, reduces the saturation of bile with cholesterol, which promotes the mobilization of cholesterol from gallstones.

It has immunomodulatory effect, influences immunological reactions in the liver: decreases the expression of some antigens on the membrane of hepatocytes, affects the number of T-lymphocytes, interleukin -2 formation, decreases the number of eosinophils.

Indications

Biliary dyskinesia, Alcoholism, Hepatitis, Liver damage, Liver cirrhosis, Colic, Gallstone disease, Pain, Constipation, Reflux esophagitis

• Chronic active hepatitis;
• toxic (incl.ч.
• drug-induced liver disease;
• alcoholic liver disease;
• non-alcoholic steatohepatitis;
• primary biliary cirrhosis of the liver;
• cystic fibrosis (cystic fibrosis) of the liver;
• dyskinesia of the biliary tract;
• biliary reflux gastritis and reflux esophagitis.

.

Active ingredient

Ursodeoxycholic acid

Composition

1 capsule contains:

the active ingredient:

ursodeoxycholic acid 250 mg;

excipients:

colloidal silicon dioxide (aerosil A -200 or A -300),

calcium hydrophosphate dihydrate,

magnesium stearate,

povidone (plasdon K-90 or collidon 90 F),

lactose monohydrate (milk sugar);

composition of the hard gelatin capsule:

casing – titanium dioxide, gelatin;

cap – titanium dioxide, gelatin, indigo carmine.

How to take, the dosage

Intravenously, without chewing, with plenty of water.

Diffuse liver disease, gallstone disease (cholesterol gallstones and biliary sludge): Exxol® is administered continuously for long time (from several months to several years) in daily dose from 10 mg/kg to 12-15 mg/kg (2-5 capsules). The duration of intake for dissolution of stones – until complete dissolution plus another 3 months for the prevention of recurrence of stone formation. In diffuse liver disease daily dose Exhol ® divided into 2-3 doses, capsules take with food. In cholelithiasis the whole daily dose is taken once at night.

Biliary reflux gastritis and reflux esophagitis: The drug is prescribed 250 mg/day (1 capsule), before bedtime. The course of treatment is from 10-14 days to 6 months, if necessary – up to 2 years.

After cholecystectomy, to prevent recurrent cholelithiasis: the recommended dose is 250 mg 2 times a day for several months.

Toxic, drug-induced liver damage, alcoholic liver disease and biliary atresia: the daily dose is set at the rate of 10-15 mg/kg in 2-3 doses. Duration of therapy is 6-12 months or more.

Primary biliary cirrhosis: the drug is prescribed at the rate of 10-15 mg/kg/day (if necessary – up to 20 mg/kg) in 2-3 times. Duration of therapy is from 6 months to several years.

Primary sclerosing cholangitis: 12-15 mg/kg/day (up to 20 mg/kg) in 2-3 times. Duration of therapy – from 6 months to several years.

Non-alcoholic steatohepatitis: 13-15 mg/kg/day in 2-3 doses. Duration of therapy – from 6 months to several years.

Mucoviscidosis: the dose is set at the rate of 20-30 mg/kg/day (up to 20 mg/kg) in 2-3 doses. Duration of therapy is from 6 months to several years. For children over 3 years old the dose is prescribed individually at the rate of 10-20 mg/kg/day.

Interaction

Antacids containing aluminum and ion exchange resins (colestyramine) reduce absorption of the drug.

Hypolipidemic drugs (especially clofibrate), estrogens, neomycin or progestins increase bile cholesterol saturation and may decrease the ability to dissolve cholesterol bile concretions.

Special Instructions

For successful dissolution it is necessary that the stones are pure cholesterol stones not more than 15-20 mm in size, the gallbladder is not more than half filled with stones and the biliary tract fully preserved its function.

When prescribing for dissolution of gallstones it is necessary to control the activity of hepatic transaminases and alkaline phosphatase, GGT, bilirubin concentration. Cholecystography should be performed every 4 weeks in the first 3 months of treatment, later – every 3 months. It is recommended to control treatment efficacy every 6 months during ultrasound investigation during the 1st year of therapy.

If elevated values persist, the drug should be discontinued. After complete dissolution of concrements it is recommended to continue use for at least 3 months in order to promote dissolution of residual concrements, the size of which is too small for their detection and for prevention of recurrence of stone formation. If partial dissolution of the concrements has not occurred within 6-12 months after the start of therapy, it is unlikely that the treatment will be effective. Detection of an invisible gallbladder during treatment is an indication that complete dissolution of the concrements has not occurred and treatment should be stopped.

Contraindications

• hypersensitivity;
• x-ray-positive (high calcium) gallstones;
• nonfunctioning gallbladder;
• biliary-gastric fistula;
• acute cholecystitis;
• acute cholangitis;
• decompensated liver cirrhosis;
• acute infectious diseases of the gallbladder, bile ducts and intestine;
• explicit hepatic and/or renal insufficiency;
• biliary tract obstruction;
• empyema of the gallbladder;
• children under 3 years of age.

With caution:children aged 3-4 years, because it may be difficult to swallow the capsules.

.

Side effects

Back pain, nausea, vomiting, diarrhea (may be dose-dependent), constipation, transient (transient) increase in liver transaminase activity, allergic reactions; rarely – calcification of gallstones, exacerbation of pre-existing psoriasis, alopecia.

.

Overdose

No cases of overdose have been identified.

In case of overdose symptomatic treatment is administered.

Similarities

Ursofalk, Ursosan, Urdoxa, Ursoliv, Ursodez, Grinterol, Urcevel, Ursodeoxycholic acid